Welcome to our dedicated page for GERON SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
Geron Corp director Robert J. Spiegel received 5,702 shares of common stock as payment for his quarterly board and committee fees. The shares were issued on 09/30/2025 and priced at $1.37 per share, based on the closing price that day. After the issuance, Spiegel beneficially owns 188,546 shares. The Form 4 was signed by an attorney-in-fact on 10/01/2025. This disclosure reflects a routine non-derivative compensation issuance to a director and reports the resulting direct ownership level.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin jointly report beneficial ownership of 43,000,000 shares of Geron Corp common stock, equal to 6.75% of the outstanding class. The filing shows the reporting persons hold shared voting and shared dispositive power and report no sole voting or dispositive power.
The ownership percentage is calculated using 636,917,758 shares outstanding per Geron's 10-Q; the filers certify the shares were not acquired to change or influence control and include a joint filing statement assigning responsibility for future amendments.
Harout Semerjian, President & CEO and a director of Geron Corp (GERN), received stock option grants on 08/07/2025 totaling 11,000,000 options exercisable into common stock at an exercise price of $1.30 per share and expiring on 08/06/2035. The awards are direct beneficial ownership and were reported on a Form 4.
The grants vest in two schedules: one award of 7,000,000 options vests with 875,000 shares on February 7, 2026 and the remaining 6,125,000 in 42 equal monthly installments beginning February 7, 2026; a second award of 4,000,000 options vests with 1,000,000 shares on August 7, 2026 and the remaining 3,000,000 in 36 equal monthly installments beginning August 7, 2026, provided the optionee continues to provide services to the Company. These details describe the size, price, expiry and service‑conditioned vesting of the executive option grants.
Geron Corporation (GERN) reports that Harout Semerjian, who serves as President, CEO and a director, filed an initial Form 3 disclosing that he does not beneficially own any securities of the company. The filing was submitted through a power of attorney signature and lists the reporting address at the company.
Event: Geron Corporation (GERN) filed an 8-K reporting the appointment of Harout Semerjian as President, Chief Executive Officer and director, effective August 7, 2025.
- CEO appointment: Mr. Semerjian replaces Dawn C. Bir and will fill a Class I board vacancy through the 2027 annual meeting.
- Compensation: Annual base salary $800,000; annual performance target bonus 70% of base salary (prorated for 2025).
- Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date.
- Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control.
- Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 months base salary, COBRA for up to 18 months; vested options remain exercisable until earlier of two years post-termination or original expiration.
- Plan amendments: Amended and Restated Severance Plan effective August 1, 2025 adds a CEO payment equal to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants.
- Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3).